What Levonorgestrel Perrigo Treats: Main Uses and Benefits

---

The medication is applied across domains where additional symptomatic support is needed, primarily within the context of reproductive health. It is considered relevant as a supportive intervention when primary methods are compromised. Its application is relevant for easing the acute risk of unintended pregnancy after a high-risk event. This is relevant in contexts involving heightened systemic burden.

This therapeutic support is commonly used across conditions presenting with acute episodes characterized by compromised or failed primary birth control. Relevant clinical scenarios include situations where primary contraceptive support has been compromised or was absent. This is applied in settings where short-term symptomatic assistance is needed to address the resulting acute exposure to pregnancy risk, providing supportive relief that helps patients cope more steadily when their intended protective measures have been nullified.

The medication provides support that helps ease the overall symptom burden related to the risk of unintended pregnancy. This intervention may be part of symptomatic management in situations where patients experience reproductive uncertainty.

“This short-term symptomatic assistance is appropriate for addressing groups of symptoms that may appear suddenly and create noticeable functional strain.”

It offers a safety net that supports patients during episodes of heightened discomfort and contributes to improved day-to-day comfort.

---

Quick Fact: Support for Acute Reproductive Risk

This medication is applied in addressing the acute exposure to pregnancy risk, providing patients with a supportive measure in emergency situations.

Regulatory References

1. Official NIH DailyMed label for Levonorgestrel

Who Can and Cannot Use Levonorgestrel Perrigo?

Regulatory documentation strictly defines the eligible population and contraindications for Levonorgestrel Perrigo, which is authorized solely for women of reproductive age, including postmenarcheal adolescents. The medicine is not indicated for use in pre-menarcheal or postmenopausal populations.

Absolute Exclusions

Use is contraindicated in cases of known or suspected pregnancy, as the medicine is not effective in terminating an existing pregnancy. It is also contraindicated for individuals with a documented hypersensitivity or allergy to levonorgestrel or any non-active ingredient in the tablet.

Restrictions and Special Considerations

The medicine is not recommended for patients with severe hepatic dysfunction or those with severe malabsorption syndromes (e.g., Crohn's disease), as efficacy may be impaired. Its use is officially restricted to an emergency basis and is not approved for routine, regular contraception. For lactating patients, Levonorgestrel is secreted into breast milk; conditional use is advised, with recommendations to interrupt nursing temporarily after administration to reduce infant exposure.

The official interaction profile for levonorgestrel emergency contraception is defined by patterns that alter the medicine’s plasma concentration, primarily through metabolic pathways. These are classified as clinically significant interactions documented in regulatory labeling.

Pharmacokinetic Interactions: Exposure Reduction

The core interaction involves a pharmacokinetic mechanism where co-administered substances induce the Cytochrome P450 3A4 ( CYP3A4) enzyme system. This results in enhanced metabolism of levonorgestrel and a documented decrease in plasma concentrations (e.g., AUC). This reduced exposure is relevant for up to 4 weeks after the discontinuation of the enzyme-inducing medicine.

Interacting Substance Category	Specific Medicines/Products Documented
CYP3A4 Inducing Medicines	Anti-epileptics (e.g., phenytoin, carbamazepine), Anti-tuberculosis agents (e.g., rifampicin), Anti-retrovirals (e.g., efavirenz, ritonavir), Griseofulvin, Bosentan.
Herbal Products	St. John's Wort (Hypericum perforatum)

Other Pharmacodynamic Interaction

A separate interaction pattern exists with Cyclosporin. Levonorgestrel is documented to inhibit the metabolism of Cyclosporin, which may lead to increased plasma levels of Cyclosporin and a risk of toxicity.

Levonorgestrel, a synthetic progestogen, acts via the following mechanistic domains, involving hormone receptor modulation and influence on reproductive physiology.

Progestogen Receptor Binding and Signaling

This domain covers Levonorgestrel's action as a progestin, engaging mechanisms that modulate signaling in the hypothalamic-pituitary-ovarian axis. It directly binds to progesterone receptors in target tissues, initiating or suppressing specific signaling sequences. This modulation of steroid hormone signaling leads to a downstream effect of suppressed gonadotropin release, particularly the luteinizing hormone (LH) surge, which is necessary for ovulation.

---

Attenuation of the Ovulatory Cascade

This domain describes the drug's influence on the key pathway associated with a reproductive response: the LH surge. By attenuating the LH surge, Levonorgestrel modifies the early molecular steps that shape systemic physiological outcomes. The resulting physiological consequence is the delay or inhibition of follicular rupture and the subsequent release of a viable egg from the ovary, resulting in suppression of reproductive axis activity.

The administration of Levonorgestrel Perrigo is a single-course oral intervention utilized only in an emergency backup capacity. The prescribed route of administration is oral, with the drug delivered in tablet form. The fundamental principle of use requires the medicine to be initiated as soon as possible following unprotected intercourse or contraceptive failure, with the treatment strictly administered within 72 hours (three days) of the event. This time-critical constraint applies regardless of the patient's current point in their menstrual cycle.

The standard labeled regimen involves a single dose of 1.5 mg taken at one time, which constitutes the entire course of treatment. An alternative, historically utilized regimen involves two 0.75 mg tablets, where the second tablet is taken 12 hours after the first, totaling the same 1.5 mg dose. The medication is explicitly not intended for routine use as a primary form of birth control.

Procedural contingencies are tied to the absorption and total dose. If the patient vomits within two hours of taking the 1.5 mg dose, a repeat dose may be required. Furthermore, a dose adjustment to a total of 3.0 mg (two 1.5 mg tablets) is considered when the patient is concurrently using certain potent enzyme-inducing drugs. The product is generally available in the United States without a prescription to women 17 years of age and older.

Research Evidence / Overview of Studies for Levonorgestrel Perrigo

This overview describes the types of research and general findings for high-dose levonorgestrel emergency contraception, focusing on what has been observed in clinical studies and what remains uncertain. This information is based on formal regulatory and peer-reviewed scientific sources.

---

Evidence for Use in Preventing Pregnancy After Unprotected Intercourse

Research on this medication primarily involves Randomized Controlled Trials (RCTs). These studies compare the outcome of taking this single-dose tablet with other established methods of emergency contraception. The findings describe group patterns related to the occurrence of pregnancy following the use of the product. Observational studies and comprehensive Systematic Reviews have also been applied in studies examining patient-reported experiences, providing additional context regarding how the medicine is observed in real-world settings.

The main focus of these trials was studied for the prevention of pregnancy after a single episode of unprotected sex or contraceptive failure. The research examined outcomes by monitoring the occurrence of pregnancy within the defined follow-up period, which generally covers the next menstrual cycle. Findings describe patterns observed in the studies related to the timing of administration. The section will summarize which patient groups and time intervals were included in the research.

---

Evaluation of Outcome Over Time and Efficacy Gaps

A key element that research explored is the time elapsed between unprotected intercourse and when the medication was taken. Studies report patterns related to the outcome when considering this timing. Data describe patterns related to the time of administration; for example, outcomes observed when administration occurred within 72 hours.

Research has also explored temporary physiological imbalance by monitoring the effect on the process of ovulation. Findings indicate that the research evaluated the relationship between administration and the Luteinizing Hormone (LH) surge, which is the hormonal signal that precedes ovulation. Studies suggest that the research indicates different outcome patterns if the medication is administered after the ovulation process has begun.

---

Studies in Special Populations: Weight and BMI

The research base has included women of reproductive age, allowing for subgroup analyses to examine outcomes in different populations. Studies have explored whether the main outcomes differ in populations with varying Body Mass Index (BMI). Specifically, some observational studies report patterns of the primary outcome in women who have a higher BMI.

However, these findings were mixed across studies, and data are still emerging. The research provides insight into short-term changes, but further analysis is still needed to establish consistent patterns.

---

Long-Term Follow-up and Extended Duration Data

The primary clinical evidence for this medication relies on studies with limited follow-up durations. The critical window for observation typically covers one menstrual cycle (up to a few weeks) to track the occurrence of the primary outcome.

There is limited information for long-term outcomes regarding the subsequent reproductive health or fertility of the women studied. Research has explored short-term symptom changes, but long-term effects on the regularity of menstrual cycles or future ability to conceive are not fully established by the primary regulatory evidence. The focus of the research has been on the acute situation, and follow-up durations were limited when attempting to explore outcomes extending beyond this defined time frame.

---

What Scientific Uncertainty and Research Gaps Remain

Despite the large amount of research, some scientific uncertainty remains. Research highlights what is known—and what is still uncertain—about the consistency of outcomes across all patient groups. For instance, data for certain groups, such as those with varying body weights, remain insufficient, and certainty remains low in these subgroups.

Furthermore, the existing studies provide limited insight into outcomes when the treatment is administered after the 72-hour window and offer limited information for long-term outcomes concerning future reproductive patterns. Research provides context but not individual predictions. The study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Levonorgestrel: MedlinePlus Drug Information
2. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index
3. Efficacy of emergency contraception and body weight

Common questions about Levonorgestrel Perrigo (FAQ)

Q: What is Levonorgestrel Perrigo used for?

A: Levonorgestrel Perrigo is indicated as an emergency contraceptive to help prevent pregnancy when taken within 72 hours (3 days) after unprotected sexual intercourse or a known contraceptive failure. It is intended for occasional, not routine, use.

Q: How does Levonorgestrel Perrigo work to prevent pregnancy?

A: The primary mechanism of action involves temporarily delaying or preventing ovulation (the release of an egg). It may also interfere with fertilization. The medication is not effective if implantation has already occurred.

Q: Is this medication the same as the abortion pill?

A: No. Levonorgestrel Perrigo is an emergency contraceptive that works primarily before pregnancy is established. It is not intended to terminate an existing pregnancy and will not be effective if the woman is already pregnant.

Q: How effective is Levonorgestrel Perrigo?

A: When taken as directed, levonorgestrel emergency contraception has been shown to significantly reduce the chance of pregnancy. Its effectiveness is highest when taken as soon as possible after unprotected intercourse. It is less effective than routine birth control methods.

Q: Are there common side effects associated with Levonorgestrel Perrigo?

A: Some people may experience side effects such as nausea, abdominal pain, fatigue, headache, dizziness, or changes in menstrual bleeding (either earlier or later than expected). These effects are generally temporary. It is important to discuss all potential side effects and risks with a healthcare professional.

Q: Will Levonorgestrel Perrigo affect my future fertility?

A: There is no evidence suggesting that the use of levonorgestrel emergency contraception negatively impacts future fertility. Fertility generally returns to normal shortly after its use.

Q: Does this medication protect against sexually transmitted infections (STIs)?

A: No. Levonorgestrel Perrigo only addresses the risk of pregnancy. It does not offer any protection against HIV/AIDS, chlamydia, gonorrhea, or other sexually transmitted infections. Barrier methods, such as condoms, are required for STI prevention.

Storage Conditions and Handling

Official regulatory labeling specifies precise conditions required to maintain the stability and integrity of Levonorgestrel 1.5 mg tablets.

Requirement	Official Statement (FDA/EMA)
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Storage must not exceed 30 C.
Protection	Protect from light and moisture. Store the tablet in its original package.
Container Integrity	Do not use if the carton is open or the blister seal is broken or missing.
Child Safety	Keep out of reach of children. In case of accidental ingestion or overdose, immediately contact a Poison Control Center or seek medical attention.

Disposal Instructions

Disposal procedures for this product are governed by local waste regulations.

Disposal Rule: Any unused medicinal product or waste material must be disposed of in accordance with local requirements. The labeling does not provide specific instructions for household disposal.